Alnylam's ALN-BCAT Study in Hepatocellular Carcinoma Evaluates Safety and Efficacy
Alnylam Pharmaceuticals is conducting a study to evaluate the safety and antitumor activity of ALN-BCAT, both alone and in combination with pembrolizumab, in patients with hepatocellular carcinoma.